logo
Nvidia's Jensen Huang thinks U.S. chip curbs failed — and he's not alone

Nvidia's Jensen Huang thinks U.S. chip curbs failed — and he's not alone

CNBC22-05-2025

Replacing Nvidia is a tall order. While Chinese competitors are years behind the company's cutting-edge technology, many analysts and insiders warn they are catching up, thanks to U.S. export restrictions.
U.S. chip restrictions on the sale of advanced semiconductor technology, especially those used in artificial intelligence, have been rolled out over several years, with the initial aim of curbing China's military advancement and protecting US dominance in the AI industry.
However, according to Nvidia CEO Jensen Huang, U.S. semiconductor export controls on China have been "a failure," causing more harm to American businesses than to China.
While the goals of cutting back the Chinese military's access to advanced U.S. technology and maintaining U.S. leadership in AI appear to have had some success on paper, loopholes and existing semiconductor stockpiles in China have complicated these aims, said Ray Wang, an independent tech and chip analyst with a focus on U.S.-China competition.
"That's partly why we are seeing a closing of the gap between Chinese and U.S. AI capabilities," added Wang.
Leaders of Nvidia and other American chip designers have long lobbied against chip controls as they worry about losing lucrative business deals. Huang said at the annual Computex technology trade show in Taipei that Nvidia's GPU market share in China fell to 50% from 95% over the past four years.
Indeed, chip experts say that the curbs create more harm than good for the U.S.
"The effects of the controls are twofold. They have the impact of reducing the ability of U.S. companies to access the China market and, in turn, have accelerated the efforts of the domestic industry to pursue greater innovation," said Paul Triolo, Partner and Senior VP for China at DGA Group.
"You create competitors to your leading companies at the same time you're cutting them off from a massive market in China," he added.
While Washington's most comprehensive export controls were passed during former U.S. President Joe Biden's term in the White House, curbs on Huawei and SMIC, China's largest chipmaker, go back to Donald Trump's first term in office.
On April 15, Nvidia disclosed that new controls, which restricted sales of its H20 graphics processing units to China, had led to a $5.5 billion charge against its revenue.
The restrictions are expected to be a boon for the demand and development of local Nvidia alternatives like Huawei, which is working on its own AI chips. They also come against the background of Beijing mobilizing billions as part of its chip self-sufficiency campaign.
"The bottom line is, the controls have incentivized China to become self-sufficient across these supply chains in a way they never would have contemplated before," Triolo said.
Chinese AI-related achievements, such as DeepSeek's R1 model and news of Huawei chip progress, have led observers to question the effectiveness of chip controls.
According Wang, the independent analyst, China's semiconductor and AI space has seen an acceleration of startups, market opportunities, and AI talent alongside the restrictions, which has clearly resulted in domestic innovations.
"I think the arguments that export controls accelerate innovation is quite valid," Wang said.
Nivida's Haung also noted these trends in April, telling lawmakers in Washington that the country has made enormous progress in the last several years and is right behind the U.S.
Nvidia's H20 chip was designed specifically to comply with existing chip controls prior to the clampdown on exports.
"We are not just talking about one export control, we are talking about a series of export controls that originate from all the way back in 2019," said Wang, noting that the evolving policies have had a couple of different objectives.
Meanwhile, in what DGA's Paul Trilio calls a "moving of the goalposts," it seems that the aims of the restrictions have shifted to an intention to slow down and contain Chinese AI and semiconductor developments.
"The continued expansion of the controls, and the lack of an articulation of what the clear end game here is, has really created a lot of issues, and created a lot of collateral damage," Trilio said, adding that it has led more people to question the policy.
In a statement earlier this month, the Information Technology & Innovation Foundation, a U.S. think tank which has received funding from various technology companies, said in a post that "the Biden administration's export control policy for AI chips has largely been a failure since day one. Yet, year after year, it has doubled down, attempting to plug various loopholes."
"While [the U.S. government] is certainly right to prevent U.S. companies from selling advanced AI technology to the Chinese military, cutting U.S. companies off from the entire commercial Chinese market is a cure worse than the disease," Stephen Ezell of ITIF told CNBC in an email.
"U.S. export controls have cost NVIDIA at least $15 billion in sales, and those are revenues the company needs to be able to earn to invest in future generations of innovation."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NVIDIA (NasdaqGS:NVDA) Collaborates With Accenture And AdaCore For AI And Automotive Innovation
NVIDIA (NasdaqGS:NVDA) Collaborates With Accenture And AdaCore For AI And Automotive Innovation

Yahoo

timean hour ago

  • Yahoo

NVIDIA (NasdaqGS:NVDA) Collaborates With Accenture And AdaCore For AI And Automotive Innovation

NVIDIA has gained attention with its recent expansion in AI startups and introduction of new programming languages for the automotive market, coinciding with a 28% share price increase in the last quarter. These developments align with the broader market's modest upward trend, as the S&P 500 and Nasdaq both marked winning streaks, lifted by renewed economic optimism and progress in trade talks with China. NVIDIA's collaboration with Accenture, AdaCore, and various industry leaders adds weight to its momentum, complementing its focus on AI and autonomous technology, which have remained key drivers of interest amid robust market conditions. We've spotted 1 possible red flag for NVIDIA you should be aware of. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent developments at NVIDIA, particularly its expansion into AI startups and new programming languages for the automotive market, could significantly influence its long-term growth narrative. The partnerships with industry giants Toyota and Uber aim to cement NVIDIA's presence in the autonomous vehicles sector, potentially boosting revenue streams and market share. These collaborations align with NVIDIA's focus on AI and autonomous technology, potentially enhancing its data center and AI workloads, which in turn might improve earnings and margin potential. Analysts have projected NVIDIA's earnings to grow substantially, assuming it capitalizes on these burgeoning opportunities. However, regulatory challenges and export controls could impact these forecasts, as uncertainty remains a persistent risk. Over the past five years, NVIDIA's total return, including share price appreciation and dividends, has been very large, reflecting significant long-term value creation. In comparison to its one-year performance, NVIDIA surpassed the US Semiconductor industry, which posted a 10.3% gain, suggesting strong relative performance. This longer-term gain is a testament to NVIDIA's rapid growth trajectory, bolstered by innovation and strategic sector expansions. Despite the impressive gains, NVIDIA's current share price of US$113.54 is significantly lower than the consensus analyst price target of US$163.12, indicating potential room for growth. As the company continues to navigate AI and automotive sectors, these market moves can be pivotal in driving future revenue and earnings. Investors may need to assess if the growth potential justifies the price target, considering the associated risks and market dynamics. The ongoing scaling of the Blackwell architecture and its implications for operational efficiency and cost management will be central to NVIDIA meeting or exceeding analyst expectations. Assess NVIDIA's future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:NVDA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

Japan's TechMagic to introduce stir-fry robots in US
Japan's TechMagic to introduce stir-fry robots in US

Yahoo

timean hour ago

  • Yahoo

Japan's TechMagic to introduce stir-fry robots in US

Japanese company TechMagic is to introduce its stir-fry robots in the US to address staffing shortages and high labour expenses, as reported by Nikkei Asia. The company anticipates Underwriters Laboratories (UL) safety certification for I-Robo2 in June 2025. The machine automates the cooking process, with a tilted, rotating cylindrical pan that automatically adjusts seasonings and heat settings. It has a self-cleaning feature, requiring human staff only for ingredient preparation and insertion. Capable of cooking 30 meals every hour, the robot can handle a range of stir-fried items such as fried noodles, chili shrimp, Chinese fried tomato and egg, pad Thai and fried rice. The high heat induction heating (IH) and rotation control of the spatula and pan movement replicate the culinary skills of experienced chefs. The machine eliminates the need to shake the frying pan, allowing anyone to cook dishes easily. TechMagic plans to lease the robots, which are currently produced in Japan, for $1,440 a month, with an additional installation fee. Its target market includes local US restaurants and Japanese chains. It intends to deploy more than 1,000 units by 2030. In Japan, the Osaka Ohsho chain of Chinese restaurants has incorporated 39 robots across 16 locations countrywide, and the Ippudo ramen chain began to use them machines for fried rice making in February 2025. TechMagic CEO Yuji Shiraki stated: "Labour costs are higher in the US than in Japan, so there's strong interest in cooking robots.' "Japan's TechMagic to introduce stir-fry robots in US" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer (NYSE:PFE) Exceeds Sales Milestone With Cresemba In Asia Pacific And China
Pfizer (NYSE:PFE) Exceeds Sales Milestone With Cresemba In Asia Pacific And China

Yahoo

timean hour ago

  • Yahoo

Pfizer (NYSE:PFE) Exceeds Sales Milestone With Cresemba In Asia Pacific And China

Pfizer announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, marking significant growth in key Asian markets. Despite this achievement, Pfizer's stock price was relatively flat last week, reflecting a broader market trend rather than significant movements unique to the company. The company's announcements, including significant clinical trial results and strategic drug market expansions, provided positive context. However, these events primarily added weight to the overall market's modest rise, suggesting a stable, yet unremarkable impact on Pfizer's share price amid ongoing economic and trade developments. Be aware that Pfizer is showing 3 risks in our investment analysis. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Pfizer's recent announcement concerning Cresemba's sales growth in Asian markets is a positive indicator for its revenue outlook. However, despite these gains, Pfizer's shares have remained flat, reflecting broader market trends rather than company-specific news. This lack of movement underscores persistent challenges, such as competition and declining utilization of key drugs like Paxlovid and Vyndaqel, potentially impacting future revenues and earnings forecasts. Over the past five years, Pfizer's total shareholder return, including dividends, was a decrease of 13.55%. This decline highlights performance concerns, particularly as Pfizer underperformed the broader US market, which recorded an 11.6% gain over the last year. Despite becoming profitable this year, Pfizer's forecasted revenue contraction of 2.1% per year over the next three years reflects ongoing challenges within the pharmaceutical industry. Pfizer's current share price at approximately US$24.41 shows a sizable discount compared to the consensus analyst price target of US$29.24. This gap suggests moderate investor skepticism about future growth, as analysts expect profit margins to rise yet predict revenue and earnings pressures. While Pfizer aims to stabilize through R&D advancements and international market penetration, these efforts will need to counteract competition's influence to align closer with the anticipated price target. Unlock comprehensive insights into our analysis of Pfizer stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store